๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Reimbursement of acetilcholinesterase inhibitors for Alzheimer's Disease in Europe

โœ Scribed by Giovanni B. Frisoni

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
73 KB
Volume
16
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

โœฆ Synopsis

Delaying the onset and progression of Alzheimer's disease (AD) is a tremendously relevant issue in western countries. It has been estimated that delaying the onset of AD-related disability by 6 months might lead to 100,000 fewer persons with AD-related disability after 10 years in the United States ( population 300 million) . Such a ยฎgure can be projected to 125,000 in the European Union ( population of about 380 million).

Eective antidementia drugs ร acetilcholinesterase inhibitors (AChI) such as donepezil and rivastigmine ร are available in most European countries that can provide symptomatic relief. Randomized clinical trials in mild to moderate AD patients have shown detectable but modest beneยฎts on cognition (Rogers et al.,

๐Ÿ“œ SIMILAR VOLUMES

Review of drug development and therapeut
Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease
โœ John J. Sramek; Victoria Zarotsky; Neal R. Cutler ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 80 KB

## Abstract Researchers have for some time appreciated the role of the neurotransmitter acetylcholine in Alzheimer's disease, and have realized the development of a number of acetylcholinesterase inhibitors. Bridging and dynabridging studies have played an important role in the development of these